Back to News
Market Impact: 0.2
The Next Chapter of B7-H3: From Systemic Disease to the Brain
Source: PR Newswire
Healthcare & BiotechTechnology & Innovation
T-MAXIMUM presented early data for its B7-H3 allogeneic CAR-T program targeting brain metastases at WCLC 2026. The provided article excerpt does not disclose efficacy, safety, patient-enrollment, or financial results, limiting assessment of the program's clinical and valuation implications.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
More News
- AI’s Grip on Financial Markets Was Never Clearer on the Way Down
- Tech stock rout, driven by US AI fears, continues in Asian trading
- Asian Markets Tally Losses From Worsening Global Rout
- Magnificent 7 loses $1 trillion. The most eye-popping stats from Thursday's tech stock plunge
- Wall Street’s best post-midterm rally in 44 years lasted just one day—then $3 trillion vanished as chip stocks plunged over AI fears
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction